Selected Publications :

Year 2004

  1. Haynes A, Sudhan Madhu, Krarup H and Singh M. Evaluation of the Malvern Spraytec with inhalation cell for the measurement of particle size distribution from metered dose inhalers. J. Pharm. Sciences, 93:349-363, 2004.
  2. Babu RJ, Kanikkannan N, Kikwai L, and Singh M. Percutaneous Absorption and Anti-Inflammatory Effect of a Substance P Receptor Antagonist – Spantide II. Pharm. Res, 21:108-113, 2004.
  3. Babu RJ, Kanikkannan N, Kikwai L, and Singh M. Preformulation stability of spantide II, a promising topical anti-inflammatory agent for the treatment of psoriasis and contact dermatitis. J. Pharmacy and Pharmacology, 56:19-25, 2004.
  4. Madhu Sudhan Shaik, Alfred Haynes, and Mandip Singh. Antiproliferative and antitumor effect of a cox-2 inhibitor, nimesulide. Clinical Cancer Research. 10: 1521-1529, 2004.
  5. Kanikkannan N, Andega S, Burton S and Singh M. Formulation and in vitro evaluation of transdermal patches of melatonin. Drug development Industrial Pharmacy. 30: 1-8, 2004.
  6. P Dayal, Shaik MS and Singh M. Evaluation of different parameters that affect droplet size distribution from nasal sprays using the Malvern Spraytec. Journal of Pharmaceutical Sciences 93, 1725:1742, 2004
  7. Madhu Sudhan Shaik, Chatterjee A and Mandip Singh. Effects of monensin liposomes on the cytotoxicity, apoptosis and expression of multidrug resistance genes in doxorubicin resistant human breast tumour (MCF-7/dox) cell-line. J. Pharmacy and Pharmacology 56:899-907, 2004.
  8. Babu RJ, Chatterjee A and Singh M. Assessment of skin irritation and molecular responses in rat skin exposed to nonane, dodecane and tetradecane. Toxicology Letters 153:255-256, 2004.
  9. R. J. Babu, A. Chatterjee, E. Ahaghotu and M. Singh. Percutaneous absorption and skin irritation upon low level prolonged dermal exposures of nonane, dodecane and tetradecane in hairless rats. Toxicology and Industrial Health, 20:109-118(2004).

Year 2005

  1. Alfred Haynes, Madhu Sudhan Shaik, Chatterjee A and Mandip Singh Formulation and Evaluation of aerosolized celecoxib for the treatment of Lung cancer. Pharmaceutical Research, 22(3):427-439, 2005.
  2. Chatterjee A, Babu RJ and Singh M. The effect of occlusive and unocclusive exposures of xylene and benzene on skin irritation and molecular responses in hairless rats. Arch Toxicology, 79:294-301(2005).
  3. E. Ahaghotu, R. J. Babu, Chatterjee, C and M. Singh. Effect of methyl substitution of benzene on the percutaneous absorption and skin irritation in hairless rats, Toxicol Lett. 159(3):261-71 (2005).
  4. Dayal, P., Pillay, V. Babu, R. and Singh, M. The use of a Box–Behnken experimental design in the development of a nasal drug delivery system of hydroxyurea: characterization of viscosity, in vitro drug release, droplet size and dynamic surface tension. Awarded 2005 AAPS Outstanding Graduate Student Research Award in Pharmaceutical technologies- AAPS PharmSciTech. 2005 Nov 17:6(4):E573-85.
  5. Loice Kikwai, R. Jayachandra Babu, R. Oliveira, Cheryl A. Armstrong, John C. Ansel and Mandip Singh. In Vitro and In Vivo Evaluation of Topical Formulations of Spantide II. Awarded 2005 AAPS Outstanding Graduate Student Research Award in Pharmaceutical technologies- AAPS PharmSciTech. 2005 Oct 31:6(4):E565-72.

Year 2006

  1. Madhu Sudhan Shaik, Abhijit Chatterjee, Tanise Jackson and Mandip Singh. Enhancement of Antitumor Activity of Docetaxel by Celecoxib in Lung Tumors. International Journal of Cancer. 118(2):396-404, 2006.
  2. Kikwai L, Babu RJ, Kanikkannan N, and Singh M. Stability and Degradation Profiles of Spantide II in Aqueous Solutions. European Journal of Pharmaceutical Sciences 27:158-166, 2006.
  3. Anticancer effect of celecoxib and aerosolized docetaxel against human non-small cell lung cancer cell line, A549. Suniket V. Fulzele, Madhu Sudhan Shaik, Abhijit Chatterjee and M. Singh. J. Pharmacy and Pharmacology. 58:1-10, 2006.
  4. Suniket V. Fulzele, Abhijit Chatterjee, Madhu Sudhan Shaik, Tanise Jackson and M. Singh. Inhalation delivery and antitumor activity of Celecoxib in human orthotopic Non-small cell lung cancer xenograft model. Pharm. Res. 23(9):2094-106, 2006.
  5. Chatterjee, A., Babu RJ, M. Klausner and Mandip Singh. In vitro and in vivo comparison of dermal irritancy of jet fuel exposure using EpiDermTM (EPI-200) cultured human skin and hairless rats. Tox.Letters 1:167(2):85-94, 2006.
  6. Zhu Donghui, Lennon SP, Peters MH, Finney WC and Mandip Singh. Brownian diffusion and surface kinetics of liposome and viral particle uptake by human lung cancer cells in vitro. Annals of Biomedical Engineering, 34(10)1573-1586, 2006.

Year 2007

  1. R. Marijani, M.S.Shaik, A.Chatterjee and M. Singh. Development of metered dose inhaler formulation of cyclosporine. J. Pharmacy and Pharmacology, 59(1):15-21, 2007.
  2. Abhijit Chatterjee, Suniket V. Fulzele, Madhu Sudhan Shaik1, Tanise Jackson, Nkechi Ichite and Mandip Singh. 15-Deoxy-D12,14-Prostaglandin J2 (15d-PGJ2) enhancesdocetaxel antitumor activity by peroxisome proliferator-activated receptor (PPAR) dependent and independent pathways in human lung cancers. Anticancer Drugs: 18(1):65-78, 2007
  3. Fulzele S, Ramapuram Jay, Singh M. Estimation of proinflammatory biomarkers of skin irritation by dermal microdialysis following exposure with irritant chemicals.Toxicology. 237(1-3):77-88, 2007.

Year 2008

  1. Jackson Tanise, Chougule Mahavir, Nkechi, Ichite, Patlolla Ram and M. Singh. Antitumor activity of Noscapine in Human Non-small cell lung cancer xenograft model. Cancer Chemother Pharmacol. 2008, 63(1):117-26.
  2. Dayal P, Babu J, Singh M. Effect of Cyclodextrins on the complexation and nasal permeation of melatonin. Drug Delivery. 2008, 15(6):381-8.

Year 2009

  1. Nkechi Ichite, Suniket V. Fulzele, Abhijit Chatterjee , Selina F. Darling-Reed, Stephen Safe and Mandip Singh. Enhancement of Docetaxel Anticancer Activity by A Novel Diindolylmethane (DIM) Compound in H460 Non-Small Cell Lung Cancer (NSCLC) Cells. Clinical Cancer Research. 2009; 15(2):543-52.
  2. Ram Patlolla, Jay Ramapuram, Mandip Singh. Dermal Microdialysis of Inflammatory Markers Induced by Aliphatic Hydrocarbons in Rats. Toxicology Letters. 2009, 185(3):168-74.
  3. Patel G, Chougule M, Singh M, Misra A, Nanoliposomal dry powder formulations, Methods in Enzymology, 2009;464:167-91.

Year 2010

  1. Mallampati R, Patlolla RR, Agarwal S, Babu RJ, Hayden P, Klausner M, Singh MSEvaluation of EpiDerm full thickness-300 (EFT-300) as an in vitro model for skin irritation: Studies on aliphatic hydrocarbons. Toxicol In Vitro. 2010, 24(2):669-76
  2. Kandimalla, K, Jayachandra Babu Ramapuram, and M. Singh. Biphasic Flux Profiles: The Yin-Yang of Transdermal Permeation Enhancement Mediated by Fatty Alcohol Enhancers. J Pharm Sci. 2010, 99(1):209-18.
  3. Patlolla R, Chougule M and Singh M. Formulation, Characterization and Pulmonary Deposition of Nebulized Celecoxib Encapsulated Nanostructured Lipid Carriers. J. Control Release, 2010, 144(2):233-41.
  4. Patlolla R, Desai P, Belay K and Singh M. Translocation of cell penetrating peptide engrafted nanoparticles across skin layers. Biomaterials, 2010; 31(21):5598-607.
  5. Desai P, Patlolla R and Singh M. Interaction of Nanoparticles and Cell Penetrating Peptides with Skin (Review). “Invited Review for Thematic issue on Nanoparticles: Crossing Barriers and Membrane Interactions, 2010, 27(7):247-59.
  6. Ichite N, Chougule M, Patel A and Singh M. Inhalation Delivery of a Novel Diindolylmethane Derivative for the Treatment of Lung Cancer. Molecular Cancer Therapeutics, 2010, 9(11):3003-14.
  7. Chougule M, Patel AR, Sachdeva P, Jackson T, Singh M. Anticancer activity of Noscapine, an opioid alkaloid in combination with Cisplatin in human non-small cell lung cancer. Lung Cancer. 2010, 71(3):271-82.

Year 2011

  1. M Chougule, A R. Patel, T Jackson, M Singh. Antitumor activity of Noscapine in combination with Doxorubicin in triple negative breast cancer. PLOS One. 2011; 6(3):e17733.
  2. Jayachandra Babu R, Dayal PP, Pawar K, Singh M. Nose-to-brain transport of melatonin from polymer gel suspensions: a microdialysis study in rats. J Drug Target. 2011, 19(9):731-40.
  3. Chougule M, Patel A, Sachdeva P and Singh MEnhanced anticancer activity of gemcitabine in combination with noscapine via antiangiogenic and apoptotic pathway against non-small cell lung cancer. Plos One, 2011;6(11), e27394.

Year 2012

  1. Shah PP, Desai P, Patel A, Singh M. Skin permeating nanogel for cutaneous inflammation using combination approach. Biomaterials. 2012. 33(5):1607-17.
  2. Shah PP, Desai P, Singh M. Effect of oleic acid modified polymeric bilayered nanoparticles on percutaneous delivery of spantide II and ketoprofen. J Control Release. 2012. 158 (2):336-345.
  3. A.R. Patel, S. D. Spencer, M. B. Chougule, M. Singh. A combined zero order/michaelis- menten limited absorption; three compartment disposition model describes the oral pharmacokinetic behavior of a highly lipophilic methylene-substituted 3, 3′-diindolylmethane (DIM) in vitamin-E TPGS. Eur J Pharm Sci. 2012, May 12;46(1-2)8-16.
  4. Shah PP*, Desai PR*, Channer D, Singh M. Enhanced skin permeation using polyarginine modified nanostructured lipid carriers. J Control Release. 2012 Aug 10;161(3):735-45.
  5. Desai P, Shah PP, Patlolla R, Singh M. Dermal microdialysis technique to evaluate the trafficking of surface modified lipid nanoparticles upon topical application. Pharm Res. 2012 Sep 29 (9):2587-600.
  6. Lee SO, Andey T, Jin UH, Kim K, Singh M, Safe S. The nuclear receptor TR3 regulates mTORC1 signaling in lung cancer cells expressing wild-type p53. Oncogene. 2012 Jul 5;31(27):3310.

Year 2013

  1. Desai P, Shah PP, Hayden P, Singh M. Investigation of follicular and non-follicular pathways for polyarginine and oleic acid modified nanoparticles. Pharm Res, 2013 May;30(5).
  2. Patel AR, Chougule MB, Patlolla R, Gwandi W, Ian T, Jackson T, M. Singh. Anticancer activity in combination of docetaxel and celecoxib nanostructured lipid carriers, Pharm Res. 2013 May;30(5):1435-46. doi: 10.1007/s11095-013-0984-9.
  3. C Godugu*, A Patel*, U Desai, M Chougule, A Sams, M. Singh. In vitro algimatrix™ 3D cell culture system, an alternative to mammalian models for non-small cell lung cancer. PLoS One. 2013;8(1):e53708. (* Contributed equally).
  4. Andey T, Patel A, Jackson T, Safe S, Singh M.1,1-Bis (3′-indolyl)-1-(p-substituted phenyl)methane compounds inhibit lung cancer cell and tumor growth in a metastasis model. Eur J Pharm Sci. 2013 Oct 9;50(2):227-41.
  5. Desai P, Marepally S, Singh M. Topical delivery of anti-TNFalpha siRNA and capsaicin via novel lipid-polymer hybrid nanoparticles efficiently inhibits skin inflammation in vivo. Journal of Controlled Release, 2013 Aug 28;170(1):51-63.
  6. Cedar H. A. Boakye, Ravi Doddapaneni, Punit P. Shah, Apurva R. Patel, Chandraiah Godugu, Stephen Safe, Santosh K. Katiyar, Singh M. Chemoprevention of skin cancer with 1,1-bis (3’-indolyl)-1-(aromatic) methane analog through induction of the orphan nuclear receptor, NR4A2 (Nurr1). PLoS One 2013 Aug 7;8(8):e69519.
  7. Godugu C, Patel AR, Doddapaneni R, Marepally S, Jackson T, Singh M. Inhalation delivery of Telmisartan enhances intratumoral distribution of nanoparticles in lung cancer models. J Control Release. 2013 Nov 28;172(1):86-95.

Year 2014

  1. Desai P, Shah PP, Parvastu A, Singh M. 31P Solid-state NMR based monitoring of permeation of cell-penetrating peptides into skin. European J of Pharmaceutical Sciences 2014 Feb;86(2):190-9.
  2. Punit Shah, Pinaki Desai, Ram Patlolla, M. Singh Effect of a combination of hydrophilic and lipophilic permeation enhancers on the skin permeation of Kahalalide F. Accepted in J. Pharmacy and Pharmacology, 2014 Jun;66(6):760-8.
  3. Patel AR, Chougule MB, Lim E, Francis KP, Safe S, Mandip SinghTheranostic tumor homing nanocarriers for the treatment of lung cancer.Nanomedicine. 2014 Jul;10(5):1053-63.
  4. Mahavir Chougule, Apurva Patel, Ram Patlolla, Mandip Singh. Epithelial transport of Noscapine across cell monolayers and influence of absorption enhancers on in vitro permeation and bioavailability: Implications for intestinal absorption. J. Drug Targeting,2014 Jul;22(6):498-508.
  5. Apurva Patel and Mandip Singh. EphA2 targeting pegylated nanocarrier drug delivery system for treatment of Lung Cancer. Pharm Res. 2014 Oct;31(10):2796-809.
  6. Terrick Andey, Srujan Marepally, Apurva Patel, Tanise Jackson, Shubhashish Sarkar, Malaney O’Connell, Pomila Singh, Mandip Singh. Cationic lipid guided short-hairpin RNA interference of Annexin A2 attenuates tumor growth and metastasis in a mouse lung cancer stem cell model. J Control Release. 2014 Jun 28;184:67-78.
  7. Jamal S, Cheriyan VT, Muthu M, Munie S, Levi E, Ashour AE, Pass HI, Wali A, Singh M, Rishi AK. CARP-1 functional mimetics are a novel class of small molecule inhibitors of malignant pleural mesothelioma cells. PLos One. 2014 Mar 5;9(3).
  8. Apurva Patel, Kevin Francis and Mandip Singh. Opening Up the Optical Imaging Window Using Nano-Luciferin. Pharm Res. 2014 Nov; 31(11):3073-84.
  9. Chandu Godugu, Apurva Patel and Mandip SinghApproaches to improve the oral bioavailability and effects of novel anticancer drugs berberine and betulinic acid. PLoS One. 2014 Mar 10;9(3):e89919. doi: 10.1371/journal.pone.0089919. eCollection 2014.
  10. Marepally S, Boakye CH, Patel AR, Godugu C, Doddapaneni R, Desai PR, Singh MTopical administration of dual siRNAs using fusogenic lipid nanoparticles for treating psoriatic-like plaques. Nanomedicine (Lond). 2014 Jul; 9 (14) 2157-74.
  11. Somagoni JBoakye CHGodugu CPatel ARMendonca Faria HAZucolotto VSingh M. Nanomiemgel-a novel drug delivery system for topical application-in vitro and in vivo evaluation. PLoS One. 2014 Dec 29;9(12).

Year 2015

  1. Cedar H. A. Boakye, Punit P. Shah, Ravi Doddapaneni, Apurva R. Patel, Stephen Safe, and Mandip Singh. Enhanced Percutaneous Delivery 1,1-bis(3-indolyl)-1-(p-chlorophenyl) Methane for skin cancer chemoprevention. J. Biomed. Nanotechnol. 2015; 11:1269-1281.
  2. Magesh Muthu, Abdelkader E. Ashour, Jagan Mohan Somagoni, Kaladhar B. Reddy, Alaa Eldeen B Yassin, Scott D. Larsen, Vino T. Cheriyan, Ahmed M. Alafeefy, Mandip Singh and Arun K. Rishi. Identification and testing of novel CARP-1 functional mimetic compounds as inhibitors of non-small cell lung and triple negative breast cancers. Journal of Biomedical Nanotechnology. 2015 Sep; 11 (9):1608-1627.
  3. Cedar Boakye, Ketan Patel and Mandip Singh. Doxorubicin liposomes as an investigative model to study the skin permeation of nanocarriers. Int J Pharm. 2015 Jul 15;489(1-2):106-16.
  4. Patel ARGodugu CWilson HSafe SSingh M. Evaluation of Spray BIO-Max DIM-P in Dogs for Oral Bioavailability and in Nu/nu Mice Bearing Orthotopic/Metastatic Lung Tumor Models for Anticancer Activity. Pharm Res. 2015 Jul; 32(7):2292-300.
  5. Andey TSudhakar GMarepally SPatel ABanerjee RSingh M. Lipid Nanocarriers of a Lipid-Conjugated Estrogenic Derivative Inhibit Tumor Growth and Enhance Cisplatin Activity against Triple-Negative Breast Cancer: Pharmacokinetic and Efficacy Evaluation. Molecular Pharmaceutics. 2015 Apr 6;12(4):1105-20.
  6. Patel ARDoddapaneni RAndey TWilson HSafe SSingh M. Evaluation of self-emulsified DIM-14 in dogs for oral bioavailability and in Nu/nu mice bearing stem cell lung tumor models for anticancer activity. J Control Release. 2015 Jun 14; 213:18-26.
  7. Hedrik E, Lee So, Doddapaneni R Singh M, Safe s. Nuclear receptor 4A1 (NR4A1) as a drug target for breast cancer chemotherapy. Endor Relat Cancer. 2015 Oct:22(5):831-40.
  8. Ketan Patel, Nusrat Chowdhury, Doddapaneni R, Cedar Boakye, Singh M. Piperlongumine for enhancing oral bioavailability and cytotoxicity of Docetaxel in Triple -negative Breast Cancer. J. Pharm. Sciences.2015 Dec; 104(12): 417-26.

Year 2016

  1. Boakye CH, Patel K, Doddapaneni R, Bagde A, Chowdhury N, Safe S, Singh M. Ultra-flexible nanocarriers for enhanced topical delivery of a highly lipophilic antioxidative molecule for skin cancer chemo prevention. Colloids Surf B Biointerfaces 2016 Jul 1;143:156-67.
  2. Patel K, Doddapaneni R, Boakye CH, Godugu C, Singh M. Tumor stromal disrupting agent enhances the anticancer efficacy of docetaxel loaded PEGylated liposomes in lung cancer. Nanomedicine (Lond), 2016 Jun;11(11):1377-92.
  3. Hedrick E, Lee SO, Doddapaneni R, Singh M, Safe S.NR4A1 Antagonists inhibit B1- Integrin-dependent Breast Cancer cell migration. Mol Cell Biol. 2016 May 1; 36(9): 1383–1394.
  4. Doddapaneni R, Patel K, Chowdhury N, Singh M. Noscapine chemosensitication enhances docetaxel anticancer activity and nanocarrier uptake in triple negative breast cancer. Exp Cell Res. 2016 Aug 1;346(1):65-73.
  5. Patel K, Doddapaneni R, Sekar V, Chowdhury N, Singh M. Combination approch of YSA peptide anchhored Docetaxel Stealth liposomes with oral antifibrotic agent for the treatment of Lung cancer. Mol Pharm. 2016 Apr 12;13(6):2049-58.
  6. Doddapaneni R, Patel K, Owaid IH, Singh M. Tumor neovasculature-targeted cationinc PEGylated liposomes of gambogic acid for the treatment of triple -negative breast cancer. Drug Deliv. 2016 May;23(4):1232-41.
  7. Lacey A, Hedrick E, Li X, Patel K, Doddapaneni R, Singh M, Safe S. Nuclear receptar 4A1 (NR4A1) as a drug targer for treating rhabdomyosarcoma (RMS).Oncotarget. 2016 May 24;7(21):31257-69.
  8. Vino T. Cheriyan, Magesh Muthu, Ketan Patel, Sreeja Sekhar, Lisa Polin, Mandip Singh, Arun Rishi, CARP-1 functional mimetics are novel inhibitor of drug-resistant triple-negative breast cancers. Oncotarget, 2016 Nov 8; 7(45): 73370–88.
  9. Godugu C, Doddapaneni R, Singh M, Safe S, Novel Diindolylmethane derivatives based NLC formulations to improve the oral Bioavailability and anticancer effects in Triple Negative Breast Cancer.European Journal of Pharmaceutics and Biopharmaceutics. 2016 Nov;108:168-179.
  10. Udofot O, Affram K, Smith T, Tshabe B, Krishnan S, Sachdeva M. Agyare E, Pharmacokinetic, biodistribution and therapeutic efficacy of 5-fluorouracil-loaded pH-sensitive PEGylated liposomal nanoparticles in HCT-116 tumor-bearing mouse. Journal of Nature and Science, 2016;2(1). pii: e171.
  11. Safe S Jin UH, Morpurgo B, Abudayyeh A, Singh M. Tjalkens RB. Nuclear receptor 4A (NR4A) family – orphans no more. J Steroid Biochem Mol Biol.2016 Mar;157:48-60.
  12. Godugu, Doddapaneni R, Patel AR, Singh R, Mercer R, Singh M. Novel Gefitinib Formulation with improved Oral Bioavailability in Treatment of A431 Skin Carcinoma. Pharm Res. 2016 Jan; 33(1): 137-154.

Year 2017

  1. Boakye CH, Patel K, Doddapaneni R, Bagde A, Marepally S, Singh M. Novel amphiphilic lipid augments the co-delivery of erlotinib and IL36 siRNA into a skin for psoriasis treatment. J Control Release. 2017 Jan 28;246:120-132.
  2. Chandraiah Godugu, Ravi Doddapaneni, Mandip Singh, Honokiol nanomicellar formulation produced increased oral bioavailability and anticancer effects in triple negative breast cancer (TNBC), Colloids and Surfaces B: Bio interfaces, 2017 May 1;153: 208-219.
  3. Nusrat Chowdhury, Imran Vohra, Ketan Patel, Ravi Doddapaneni, Arindam Mondal, Mandip Singh, Liposomes Co-loaded With 6-Phosphofructo-2-Kinase/Fructose-2, 6-Biphosphatase 3 (PFKFB3) shRNA Plasmid And Docetaxel For The Treatment Of Non-Small Cell Lung Cancer, Pharm Res (2017). Pharm Res. 2017 Nov; 34(11): 2371-2384.
  4. Shallu Kutlehria, Gautam Behl, Ketan Patel, Ravi Doddapaneni, Nusrat Chowdhury, Arvind Bagde, Imran Vhora, Mandip Singh, Cholecalciferol-PEG conjugate based nanomicelles of doxorubicin for treatment of triple negative breast cancer, AAPS PharmaSciTech, (2017);19(83). https://doi.org/10.1208/s12249-017-0885-z.
  5. Kevin Affram, Ofonime Udofot, Mandip Singh, Sunil Krishnan, Rosenberg, Rene Reams and Edward Agyre, Smart thermosensitive liposomes for effective solid tumor therapy and in vivo imaging, PLoS One. 2017 Sep; 12(9): e0185116.
  6. Ravi Doddapaneni, Ketan Patel, Nusrat Chowdhury & Mandip Singh, Reversal of drug-resistance by noscapine chemo-sensitization in docetaxel resistant triple negative breast cancer, Scientific Reports 7, Article number: 15824(2017) doi:10.1038/s41598-017-15531-1.

Year 2018

  1. Arvind Bagde, Arindam Mondal, Mandip Singh. Drug delivery strategies for chemoprevention of UV-B induced skin cancer: a Review, Photodermatology, photoimmunology and photomedicine, 2018 Jan; 34: 60–68.
  2. Shallu Kutlehria, Imran Vhora, Arvind Bagde, Nusrat Chowdhury, Gautam Behl, Ketan Patel, Mandip Singh. Tacrolimus loaded PEG-Cholecalciferol based Nanomicelles for Treatment of Ocular Inflammation. Pharmaceutical Res. 2018 Apr 16;35(6):117.
  3. Nusrat Chowdhury, Imran Vhora, Ketan Patel, Arvind Bagde, Shallu Kutlehria and Mandip Singh. Development of hot melt extruded solid dispersion of tamoxifen citrate and resveratrol for synergistic effects on breast cancer cells, AAPS PharmSciTech (2018). https://doi.org/10.1208/s12249-018-1111-3.
  4. Cheriyan, V. T., Alsaab, H., Sekhar, S., Venkatesh, J., Mondal, A., Vhora, I., … Rishi, A. K. (2018). A CARP-1 functional mimetic compound is synergistic with BRAF-targeting in non-small cell lung cancers. Oncotarget, 9(51), 29680-29697. http://doi.org/10.18632/oncotarget.25671.

Year 2019

  1. Arvind Bagde, Ketan Patel, Arindam Mondal, Shallu Kutlehria, Nusrat Chowdhury, Aragaw Gebeyehu, Nilkumar Patel, Nagi Kumar, Mandip Singh,Combination of UVB absorbing Titanium dioxide and Quercetin Nanogel for skin cancer chemoprevention, AAPS PharmSciTech, June 2019, 20: 240. https://doi.org/10.1208/s12249-019-1424-x
  2. Arvind Bagde, Ketan Patel, Shallu Kutlehria, Nusrat Chowdhury, Mandip Singh, Formulation of topical Ibuprofen solid lipid nanoparticle (SLN) gel using hot melt extrusion technique (HME) and determining its anti-inflammatory strength, Drug Delivery and Translational Research. March 2019, https://doi.org/10.1007/s13346-019-00632-3.
  3. Ebony Nottingham, Arindam Mondal, Vasantkumar Sekar, A Rishi, Steven Safe, Mandip Singh, The role of Self Nano Emulsifying drug delivery systems of CDODA-Me in sensitizing EGFR resistant Non-small cell lung cancer(HCC827) to Erlotinib, Journal of Pharmaceutical Sciences (under review)
  4. Ebony Nottingham, Elizabeth Mazzio, Shallu Kutlehria, Ramesh Badisa, Mandip Sachdeva “Whole transcriptomic analysis to delineate major synergistic effects of methyl 2-cyano-3,11-dioxo-18beta-olean-1,12-dien-30-oate (CDODA-Me) and Erlotinib in (ERL) in ERL resistant lung cancer HCC827 cells” Lung Cancer (Under Review)
  5. Terrick Andey, PhDa, NamrataBora-Singhal, Srikumar Chellappan, Mandip Singh, Cationic lipoplexes for treatment of cancer stem cell-derived murine2lung tumors. Nanomedicine: Nanotechnology, Biology and Medicine. March 2019. doi: 10.1016/j.nano.2019.02.007
  6. Ketan Patel, Ravi Doddapaneni, Manali Patki, Vasantkumar Sekar, Arvind Bagde, Mandip Singh, Erlotinib-valproic acid liquisolid formulation: Evaluating oral bioavailability and cytotoxicity in erlotinib resistant non-small cell lung cancer cells AAPS PharmSciTech. April 2019, 20:135.
  7. Shallu Kutlehria, Arvind Bagde, Neal Patel, Mandip Singh, “Whole eye perfusion model for screening of the ocular formulations via confocal laser scanning microscopy, AAPS PharmSciTech. August 2019. (Accepted).
  8. Peddakkulappagari, CS, Saifi, MA, Khurana, A, Anchi, P, Mandip Singh, Godugu, C. Withaferin A ameliorates renal injury due to its potent effect on inflammatory signaling. BioFactors. 2019; 1– 13. https://doi.org/10.1002/biof.1534
  9. Sayed, N, Khurana, A, Saifi, MA, Mandip Singh, Godugu, C. Withaferin A reverses bile duct ligation‐induced liver fibrosis by modulating extracellular matrix deposition: Role of LOXL2/Snail1, vimentin, and NFκB signaling. BioFactors. 2019; 1– 16. https://doi.org/10.1002/biof.1546